Dr L. Boekel (Laura)
Onderzoeker
'In 2019 ben ik begonnen met mijn wetenschappelijke stage bij Reade in de onderzoekslijn van prof. Mike Nurmohamed. Toen de COVID-19 pandemie begon ben ik daarna in de lijn van prof. Gertjan Wolbink als PhD-student gaan werken. Tijdens deze periode hebben we binnen Reade en het Amsterdam UMC een grootschalig prospectief onderzoek opgezet waarmee we tijdens de pandemie veel verschillende vragen voor reumapatiënten hebben kunnen beantwoorden, zoals vragen omtrent risico’s om ernstig ziekt te worden van COVID-19, de vaccinatierespons en bijwerkingen van vaccinaties. Dit resulteerde in 2024 in een Cum laude promotie. Naast mijn promotieonderzoek heb ik de opleiding tot epidemioloog afgerond en inmiddels werk ik als postdoc-onderzoeker bij Reade.'
Gediplomeerd specialist sinds
2019
Bij Reade sinds
2019
Opleiding(en)
Geneeskunde (bachelor), Epidemiologie en statistiek (master)
Werkervaring
- 2020 – 2024 PhD student
- 2024 – heden Post-doc/epidemioloog
Promotie
COVID-19 in patients with immune-mediated inflammatory diseases – scientific answers to changing medical challenges using a patient-interactive research platform
Afgerond op 28-02-2024
Talen
Nederlands, Engels
Publicaties
- Boekel L. Protecting patients with SLE against herpes zoster: time for early proactive vaccine counselling. Lancet Rheumatol. 2024;6(6):e331-e333. doi:10.1016/S2665-9913(24)00115-2
- Boekel L, Atiqi S, Leeuw M, et al. Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands. Lancet Rheumatol. 2023;5(7):e375-e385. doi:10.1016/S2665-9913(23)00127-3
- Boekel L, Besten YR, Hooijberg F, et al. SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period. Lancet Rheumatol. 2022;4(11):e747-e750. doi:10.1016/S2665-9913(22)00221-1
- Boekel L, Stalman EW, Wieske L, et al. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. Lancet Rheumatol. 2022;4(6):e417-e429. doi:10.1016/S2665-9913(22)00102-3
- Boekel L, Hooijberg F, Besten YR, et al. COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases. Lancet Rheumatol. 2022;4(5):e310-e313. doi:10.1016/S2665-9913(22)00009-1
- Boekel L, Wolbink GJ. Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients. Lancet Rheumatol. 2022;4(3):e154-e155. doi:10.1016/S2665-9913(21)00418-5
- Boekel L. Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis. Lancet Rheumatol. 2022;4(1):e5-e7. doi:10.1016/S2665-9913(21)00360-X
- Boekel L, Steenhuis M, Hooijberg F, et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol. 2021;3(11):e778-e788. doi:10.1016/S2665-9913(21)00222-8
- Boekel L, Kummer LY, van Dam KPJ, et al. Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. Lancet Rheumatol. 2021;3(8):e542-e545. doi:10.1016/S2665-9913(21)00181-8
- Boekel L, Hooijberg F, van Kempen ZLE, et al. Perspective of patients with autoimmune diseases on COVID-19 vaccination. Lancet Rheumatol. 2021;3(4):e241-e243. doi:10.1016/S2665-9913(21)00037-0
- Boekel L, Hooijberg F, Vogelzang EH, et al. Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study. RMD Open. 2022;8(1):e002035. doi:10.1136/rmdopen-2021-002035
- Boekel L, Hooijberg F, Vogelzang EH, et al. Spinning straw into gold: description of a disruptive rheumatology research platform inspired by the COVID-19 pandemic. Arthritis Res Ther. 2021;23(1):207. Published 2021 Aug 5. doi:10.1186/s13075-021-02574-z
- Vlot MC, Boekel L, Kragt J, et al. Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)2D, but No Difference in Ratio of 25(OH)D/24,25(OH)2D and FGF23 Concentrations. Nutrients. 2019;11(11):2774. Published 2019 Nov 15. doi:10.3390/nu11112774
- Pier M, Wolbink G, Boekel L. Time to talk to adults with rheumatic diseases about herpes zoster vaccination. Lancet Rheumatol. 2024;6(4):e247-e251. doi:10.1016/S2665-9913(24)00019-5
- Hooijberg F, Boekel L, Vogelzang EH, et al. Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. Lancet Rheumatol. 2020;2(10):e583-e585. doi:10.1016/S2665-9913(20)30286-1
- Wieske L, van Dam KPJ, Steenhuis M, et al. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol. 2022;4(5):e338-e350. doi:10.1016/S2665-9913(22)00034-0
- Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768-779. doi:10.1136/annrheumdis-2021-221733
- Baniaamam M, Heslinga SC, Boekel L, et al. The Prevalence of Cardiac Diseases in a Contemporary Large Cohort of Dutch Elderly Ankylosing Spondylitis Patients-The CARDAS Study. J Clin Med. 2021;10(21):5069. Published 2021 Oct 29. doi:10.3390/jcm10215069
